Whats new
Whats new.
CLSA Equity Research - LAG-3 launch pad - FDA approval of LAG-3 therapy a key milestone for the sector (ASX:IMM) (Analyst: Andrew Paine)
March 20th 2022
For a copy of this research report please contact your CLSA advisor.
Whats new
March 20th 2022
For a copy of this research report please contact your CLSA advisor.